Milestone Pharmaceuticals Inc. (MIST) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -78.38M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 16.22M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-78.38M | (m) | (m) | $16.22M | (m) | (m) |
| 2026-03-31 | $-65.28M | (m) | (m) | $16.38M | (m) | (m) |
| 2025-12-31 | $-62.14M | (m) | (m) | $18.11M | (m) | (m) |
| 2025-09-30 | $-57.23M | (m) | (m) | $16.53M | (m) | (m) |
| 2025-06-30 | $-55.02M | (m) | (m) | $16.55M | (m) | (m) |
| 2025-03-31 | $-52.15M | (m) | (m) | $15.70M | (m) | (m) |
| 2024-12-31 | $-42.10M | (m) | (m) | $14.36M | (m) | (m) |
| 2024-09-30 | $-43.55M | (m) | (m) | $15.87M | (m) | (m) |
| 2024-06-30 | $-49.30M | (m) | (m) | $18.63M | (m) | (m) |
| 2024-03-31 | $-56.07M | (m) | (m) | $24.43M | (m) | (m) |
| 2023-12-31 | $-61.10M | (m) | (m) | $31.05M | (m) | (m) |
| 2023-09-30 | $-61.06M | (m) | (m) | $36.18M | (m) | (m) |
| 2023-06-30 | $-60.73M | (m) | (m) | $39.28M | (m) | (m) |
| 2023-03-31 | $-61.10M | (m) | (m) | $41.32M | (m) | (m) |
| 2022-12-31 | $-59.64M | (m) | (m) | $39.83M | (m) | (m) |
| 2022-09-30 | $-62.80M | (m) | (m) | $40.17M | (m) | (m) |
| 2022-06-30 | $-62.04M | (m) | (m) | $40.07M | (m) | (m) |
| 2022-03-31 | $-44.53M | (m) | (m) | $38.84M | (m) | (m) |
| 2021-12-31 | $-43.07M | (m) | (m) | $38.67M | (m) | (m) |
| 2021-09-30 | $-34.92M | (m) | (m) | $33.52M | (m) | (m) |
| 2021-06-30 | $-32.73M | (m) | (m) | $32.02M | (m) | (m) |
| 2021-03-31 | $-46.55M | (m) | (m) | $31.21M | (m) | (m) |
| 2020-12-31 | $-50.71M | (m) | (m) | $34.49M | (m) | (m) |
| 2020-09-30 | $-60.84M | (m) | (m) | $42.87M | (m) | (m) |
| 2020-06-30 | $-62.48M | (m) | (m) | $44.19M | (m) | (m) |
| 2020-03-31 | $-63.71M | (m) | (m) | $46.09M | (m) | (m) |
| 2019-12-31 | $-57.88M | (m) | (m) | $41.98M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-23.82M | (m) | (m) | $16.85M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |